Skip to main content
Fig. 6 | Molecular Medicine

Fig. 6

From: Pan-cancer analysis reveals RIPK2 predicts prognosis and promotes immune therapy resistance via triggering cytotoxic T lymphocytes dysfunction

Fig. 6

Mechanisms of RIPK2 promoting immunotherapy resistance. A The relationship between RIPK2 and CTL dysfunction. B The correlation of RIPK2 and known immune checkpoints marker through all TCGA cancers (*p < 0.05, **p < 0.01, and ***p < 0.001). C GSEA analysis for SKCM and KIRC samples with high RIPK2 expression and low expression. D The correlation of RIPK2 and IFNG, STAT1, IFNAR1 in SKCM and KIRC. E The correlation of RIPK2 and the key components of IL-6/JAK/STAT3 signaling. F Change of RIPK2 expression after pathogen infection

Back to article page

Molecular Medicine

ISSN: 1528-3658